07Nov
07Nov
Siamab’s Antibody-drug Conjugates for Ovarian Cancer Seen to Succeed in Animal Models
Siamab Therapeutics’ preclinical work with anti-STn antibody-drug conjugates is moving forward, and in animal models — including primates — it showed the conjugates could safely and effectively treat ovarian cancer resistant to chemotherapy. Read more >>
04Nov
Myomo Enters Canadian Market
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a commercial stage medical robotics company, today announced that its Application for a Canadian Medical Device License has been approved by Health Canada. With the license, Myomo and its distribution partner, Ottobock, are now entering the Canadian market for commercial sale of the MyoPro myolelectric arm orthosis (powered brace). Read more >>
04Nov
Corbus Pharmaceuticals Receives Anabasum Patent for Inflammatory, Fibrotic Diseases
Corbus Pharmaceuticals recently announced that the U.S. Patent and Trademark Office has issued a patent for the use of anabasum, the company’s lead therapy candidate for the treatment of inflammatory and fibrotic diseases. Read more >>
02Nov
Video Ad Tech Company Pixability Is Now a Facebook Marketing Partner
October was a big month for video advertising technology company Pixability. Earlier this month, the company announced that it was named as a Snapchat Certified Partner. And this week, Pixability became a Facebook Marketing Partner. Read more >>
01Nov
Siamab Therapeutics Presents New PreClinical Safety Data
Siamab Therapeutics, Inc., a biopharmaceutical company developing novel cancer immunotherapies, today announced the presentation of new preclinical data demonstrating the safety of its novel anti-Sialyl-Tn (STn) antibody drug conjugates (ADCs) in multiple animal models, including non-human primates (NHPs). These results add to the company’s efficacy data findings showing that its anti-STn antibody therapeutics inhibit tumor progression in cell-line-derived and patient-derived xenograft (PDX) ovarian cancer and pancreatic cancer mouse models, with complete regression observed in some treatment arms. The preclinical efficacy...
01Nov
Regroup to Host Live Webinar on Active Shooter Preparedness for Large Venues and High Rises
Regroup Mass Notification, the award-winning leader in emergency and day-to-day communication technology, today announced a joint alliance with Alvarez Associates, industry leader in workplace violence prevention, to present an online webinar on critical strategies for preparing for and responding to active shooter events at large venues. Read more >>
28Oct
EDUCAUSE Preview: Protect Your Students and Faculty With Regroup
Regroup Goes Above and Beyond To Provide College Campuses With A Reliable, Feature Packed Mass Notification Platform. Read more >>
28Oct
He can’t wait to use his eSight glasses to see his mom’s face.
He can't wait to use his eSight glasses to see his mom's face. ❤ on Dose. Read more >>
26Oct